► EAA Supports
Efficacy and Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis
You can make a difference for yourself and the millions of individuals living with atopic dermatitis by participating in research. Below is a clinical trial recruiting in your area. Please consider your potential impact and click on the link to learn more.
Currently Enrolling – Atopic Dermatitis Clinical Trial
Now enrolling for a phase 3 clinical trial of an investigational medication for atopic dermatitis, also known as eczema. Study participants must be at least 12 years of age or older. This study will compare injections of nemolizumab (CD14152) to placebo (placebo looks like the study medication but contains no active drug). All study-related care and study medication will be provided at no charge. Reimbursement for time and participation may be available, if applicable. Visit www.arcadiastudy.com for more information.